There may be some good news developing for those who suffer from Pompe Disease. Amicus Therapeutics, Inc. (NASDAQ: FOLD) has reported pre-clinical data from its Pompe disease gene therapy program and the results will…
Drugmaker Pfizer beat estimates on both the top and bottom lines for the first quarter, and shares rallied after the report.
While measles has a number of telling symptoms, many are common with other infections. One, however, is a telltale sign that someone has the disease.
The April 15 short interest data have been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The April 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The April 15 short interest data have been compared with the previous figures, and short interest moves in these selected marijuana stocks were mixed.
Even though tech stocks on average are posting far better gains that health care stocks, a fair number of health care stocks — biotechs specifically — are blowing these tech stocks out of the…
24/7 Wall St. has looked over some of the biotech sector's laggards, and we have also looked over the top exchange-traded funds for a breakdown of what they own to show how much they…
Jefferies did a deep dive into the health care sector, looking for underperforming stocks that could hold some solid value going forward.
Mustang Bio shares more than doubled on Thursday after the company announced a breakthrough that cured eight infants dealing with the "Bubble Boy" immune disorder.
CRISPR Therapeutics shares jumped on Tuesday after the firm announced that the FDA has granted Fast Track Designation for its treatment for transfusion-dependent beta thalassemia.
Johnson & Johnson released better-than-expected first-quarter financial results before the markets opened on Tuesday.
UnitedHealth was the second-worst performer among the Dow Jones industrials this year. But with everything seemingly going the right way now, is it poised for a turnaround?
Johnson & Johnson is scheduled to release its first-quarter financial results before the markets open on Tuesday, and expectations are muted.
Clovis Oncology may have thought that it could sneak an announcement by late on Friday, but its shares were definitely paying the price Monday morning.
